Arcutis Biotherapeutics, Inc. (ARQT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$26.41

From 52W high−18.65%

Volume18.97M

Market cap$3.19B

P/E (TTM)114.9x

P/S (TTM)6.9x

Div yield—

Key dataSep 18, 2026

Open

$26.41

From 52W high

−18.65%

Volume

18.97M

Market cap

$3.19B

ValuationView details →

P/E (Fwd)

31.5x

EV/EBITDA

69.5x

P/E (TTM)

114.9x

RSI (14)

53.6

MomentumView details →

1D Return

−4.08%

YTD Return

−12.00%

SummaryUpdated Jun 1, 2026

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage biopharmaceutical company founded in 2016 and headquartered in Westlake Village, California. The company went public in January 2020 and focuses on developing and commercializing innovative treatments for dermatological diseases. Arcutis has successfully transitioned from a clinical-stage company to a commercial enterprise, with its flagship product ZORYVE generating significant revenue growth since its initial launch for plaque psoriasis in 2022.

Ask drillr about Arcutis Biotherapeutics, Inc. →

ValuationView details →

P/E (Fwd)

31.5x

P/E (TTM)

114.9x

EV/EBITDA

69.5x

EV/Sales

6.6x

P/S (TTM)

6.9x

P/B (TTM)

14.5x

ProfitabilityView details →

Gross Margin

91.14%

Net Margin

6.15%

EBITDA Margin

9.51%

ROE (TTM)

12.93%

ROA (TTM)

5.84%

Asset Turnover

0.98x

GrowthView details →

Revenue YoY

+76.11%

EPS YoY

+129.47%

FCF YoY

+154.89%

Revenue CAGR 3Y

+367.27%

EPS CAGR 3Y

+88.79%

EBITDA YoY

+164.40%

MomentumView details →

1D Return

−4.08%

YTD Return

−12.00%

1Y Return

+47.04%

RSI (14)

53.6

vs 50D SMA

−1.51%

vs 200D SMA

+0.67%

Capital & dividendView details →

Debt/Equity

0.52x

Current Ratio

2.92x

Quick Ratio

2.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$0.11

EPS Surprise

99.71%

Beats (12Q)

8/12

Next Q EPS Est

$0.19

Avg Surprise (4Q)

27.71%

Rev Surprise

9.26%

Financials snapshotView financials →

Revenue (TTM)

463.98M

Net Income (TTM)

28.52M

Op. CF (TTM)

39.31M

Next earningsOct 27, 2026 →

Latest newsMore news →

Arcutis Biotherapeutics (ARQT) shares rose 11.2% in the previous trading session on higher-than-average volume.3d ago

Dow Jones Indices announced changes to the S&P 600 index, adding ten companies and removing ten others, effective before the open on September 21, 2026, as part of the quarterly rebalance.16d ago

Similar companies

Dyne Therapeutics, Inc.DYN Veracyte, Inc.VCYT Arcus Biosciences, Inc.RCUS Denali Therapeutics Inc.DNLI 之江生物688317.SH Laekna, Inc.02105.HK Find similar companies →

Latest newsMore news →

Arcutis Biotherapeutics (ARQT) shares rose 11.2% in the previous trading session on higher-than-average volume.3d ago Dow Jones Indices announced changes to the S&P 600 index, adding ten companies and removing ten others, effective before the open on September 21, 2026, as part of the quarterly rebalance.16d ago